Pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers.
Cellestia Biotech is a clinical-stage biopharmaceutical company developing first-in-class therapeutics targeting the Notch signaling pathway for the treatment of multi-drug resistant cancers and autoimmune diseases. Its lead candidate CB-103, an oral pan-Notch inhibitor, has demonstrated safety and biological activity in Phase 1 trials and is advancing into Phase 2 for hematologic and solid tumor cancers, as well as proof-of-concept studies in graft-versus-host disease. Founded on pioneering academic research, Cellestia addresses cancers where conventional therapies fail by exploiting a novel mode of transcriptional inhibition distinct from prior Notch-targeting approaches.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2018
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...

Global clinical research organization specializing in early-stage clinical trials and bioanalytic...
Healthcare company applying technology to drug development by building nimble biotech subsidiarie...
Neuralink is building a brain-computer interface for medical needs and greater human potential.